fda warning letters compounded semaglutide tirzepatide 2025 US sends 25 to telehealth companies over claims on weight-loss drugs Fifth Circuit probes FDA ban

The Rs 10,000-crore opportunity According to the Elara Securities report, the GLP-1 drug category (used for diabetes and obesity) could grow to represent 4-5% of the entire Indian pharma market

Unlike semaglutide, which targets one hormone pathway, tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two separate hormone systems involved in appetite regulation and metabolism

Neither version holds a marketing authorisation in any jurisdiction

Some patients benefit from the ability to adjust doses more frequently or combine medications, which may be more readily available through online services

You value a completely "clean" biological profile that ignores stress hormones like cortisol